



# DURECT Corporation Invites You to Join its Fourth Quarter 2016 Earnings Conference Call

CUPERTINO, Calif., Feb. 24, 2017 /PRNewswire/ — In conjunction with DURECT Corporation's (Nasdaq: DRRX) fourth quarter 2016 financial results press release, you are invited to listen to a conference call that will be broadcast live over the internet on Tuesday, March 14, 2017 at 4:30 pm Eastern Time (1:30 pm Pacific Time).

A live audio webcast of the presentation will be available by accessing DURECT's homepage at [www.durect.com](http://www.durect.com) and clicking "Investor Relations." If you are unable to participate during the live webcast, the call will be archived on DURECT's website under Audio Archive in the "Investor Relations" section.

## About DURECT Corporation

DURECT is a biopharmaceutical company actively developing new therapeutics based on its Epigenetic Regulator Program and proprietary drug delivery platforms. DUR-928, a new chemical entity in Phase 1 development, is the lead candidate in DURECT's Epigenetic Regulator Program. An endogenous, orally bioavailable small molecule, DUR-928 has been shown in preclinical studies to play an important regulatory role in lipid homeostasis, inflammation, and cell survival. Human applications may include acute organ injury and chronic metabolic diseases such as nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH) and other liver diseases both broad and orphan. DURECT's advanced oral, injectable, and transdermal delivery technologies are designed to enable new indications and enhanced attributes for small-molecule and biologic drugs. One late-stage product candidate in this category is POSIMIR<sup>®</sup> (SABER<sup>®</sup>-Bupivacaine), an investigational analgesic product intended to address key unmet needs in postoperative pain management. Another late stage product candidate is REMOXY<sup>®</sup> ER (oxycodone), an investigational new drug based on DURECT's ORADUR<sup>®</sup> technology. For more information, please visit [www.durect.com](http://www.durect.com).

NOTE: POSIMIR<sup>®</sup>, SABER<sup>®</sup>, and ORADUR<sup>®</sup> are trademarks of DURECT Corporation. Other referenced trademarks belong to their respective owners. POSIMIR, REMOXY ER and DUR-928, are investigational drugs under development and have not been approved for sale by the U.S. Food and Drug Administration or other health authorities.

To view the original version on PR Newswire, visit <http://www.prnewswire.com/news-releases/durect-corporation-invites-you-to-join-its-fourth-quarter-2016-earnings-conference-call-300413482.html>

SOURCE DURECT Corporation

Matt Hogan, Chief Financial Officer, DURECT Corporation, 408-777-4936; Matthew Duffy, Managing Director, LifeSci Advisors, 212-915-0685